JPWO2020139830A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020139830A5
JPWO2020139830A5 JP2021537818A JP2021537818A JPWO2020139830A5 JP WO2020139830 A5 JPWO2020139830 A5 JP WO2020139830A5 JP 2021537818 A JP2021537818 A JP 2021537818A JP 2021537818 A JP2021537818 A JP 2021537818A JP WO2020139830 A5 JPWO2020139830 A5 JP WO2020139830A5
Authority
JP
Japan
Prior art keywords
nucleic acid
alox15
acid molecule
seq
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021537818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515838A5 (https=
JP2022515838A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/068328 external-priority patent/WO2020139830A2/en
Publication of JP2022515838A publication Critical patent/JP2022515838A/ja
Publication of JPWO2020139830A5 publication Critical patent/JPWO2020139830A5/ja
Publication of JP2022515838A5 publication Critical patent/JP2022515838A5/ja
Pending legal-status Critical Current

Links

JP2021537818A 2018-12-28 2019-12-23 アラキドン酸15-リポキシゲナーゼ(alox15)阻害剤による呼吸器障害の治療 Pending JP2022515838A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862785899P 2018-12-28 2018-12-28
US62/785,899 2018-12-28
PCT/US2019/068328 WO2020139830A2 (en) 2018-12-28 2019-12-23 Treatment of respiratory disorders with arachidonate15-lipoxygenase (alox15) inhibitors

Publications (3)

Publication Number Publication Date
JP2022515838A JP2022515838A (ja) 2022-02-22
JPWO2020139830A5 true JPWO2020139830A5 (https=) 2022-12-13
JP2022515838A5 JP2022515838A5 (https=) 2022-12-13

Family

ID=69326713

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021537818A Pending JP2022515838A (ja) 2018-12-28 2019-12-23 アラキドン酸15-リポキシゲナーゼ(alox15)阻害剤による呼吸器障害の治療

Country Status (12)

Country Link
US (2) US12472241B2 (https=)
EP (1) EP3902567A2 (https=)
JP (1) JP2022515838A (https=)
KR (1) KR20210110623A (https=)
CN (1) CN113423435A (https=)
AU (1) AU2019417718B2 (https=)
CA (1) CA3124670A1 (https=)
IL (1) IL284046A (https=)
MX (1) MX2021007938A (https=)
NZ (1) NZ777336A (https=)
SG (1) SG11202106517WA (https=)
WO (1) WO2020139830A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3911632A1 (en) 2019-01-15 2021-11-24 Empirico Inc. Prodrugs of alox-15 inhibitors and methods of using the same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932425A (en) 1997-02-18 1999-08-03 Signal Pharmaceuticals, Inc. Compositions and methods for modulating cellular NF-κB activation
US6297248B1 (en) 1997-04-06 2001-10-02 Suntory Limited 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor
FR2762841B1 (fr) 1997-04-30 1999-07-02 Jouveinal Inst Rech Diazepino-indolones inhibitrices de phosphodiesterases iv
IT1296984B1 (it) 1997-12-19 1999-08-03 Zambon Spa Derivati ftalazinici inibitori della fosfodiesterasi 4
TR200003130T2 (tr) 1998-04-28 2001-01-22 Arzneimittelwerk Dresden Gmbh Yeni hidroksiindoller, bunların fosfodiesteraz 4 inhibitörleri olarak kullanımları ve hazırlanmaları için işlemler
US6303789B1 (en) 1998-06-10 2001-10-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors
IT1302677B1 (it) 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
IT1303272B1 (it) 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
US6686502B1 (en) 1999-03-26 2004-02-03 Ucb S.A. Compounds and methods for treatment of asthma, allergy and inflammatory disorders
US6740666B2 (en) 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
JP4460221B2 (ja) 2001-05-24 2010-05-12 メルク フロスト カナダ リミテツド 1−ビアリール−1,8−ナフチリジン−4−オン系ホスホジエステラーゼ−4阻害薬
JO2311B1 (en) 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
IS7839A (is) 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
MY141255A (en) 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
EP2959899B1 (en) 2011-08-23 2017-02-22 Cornerstone Therapeutics Inc. Use of zileuton for the treatment of nasal polyps in cystic fibrosis patients
US10132809B2 (en) 2012-10-10 2018-11-20 Rhote Island Hospital Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis
AU2014284235C1 (en) 2013-06-21 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods for treating nasal polyposis by administering an IL-4R antagonist
US20210361693A1 (en) 2018-02-09 2021-11-25 Empirico Inc. Process to inhibit or eliminate eosinophilic diseases of the airway and related conditions

Similar Documents

Publication Publication Date Title
Nakamori et al. A slipped-CAG DNA-binding small molecule induces trinucleotide-repeat contractions in vivo
JP3693352B2 (ja) プローブアレイを使用して、遺伝子多型性を検出し、対立遺伝子発現をモニターする方法
AU2008316313B2 (en) A method of diagnosing neoplasms - II
US20090062131A1 (en) Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases
US9273356B2 (en) Methods and kits for linking polymorphic sequences to expanded repeat mutations
EP2298937A1 (en) Methods and kits for linking polymorphic sequences to expanded repeat mutations
KR102029775B1 (ko) 비근침윤성 방광암 진단용 바이오마커 및 이의 용도
WO2008064519A1 (en) Methods and compositions for diagnosis of esophageal cancer and prognosis and improvement of patient survival
Dokun et al. Relationship of SNCG, S100A4, S100A9 and LCN2 gene expression and DNA methylation in bladder cancer
JPWO2020154268A5 (https=)
JP2008545390A (ja) 遺伝的多型を用いた肺癌を発達させるリスクの評価方法
JP2001054400A (ja) 遺伝子型決定二対立遺伝子マーカー
JP7729608B2 (ja) 膀胱癌治療におけるbcg膀胱内注入療法の治療効果を予測するためのバイオマーカー、方法、キット及びアレイ
JPWO2020139830A5 (https=)
US20160312311A1 (en) Markers for isocitrate dehydrogenase inhibitors
JP7574206B2 (ja) ステロール調節エレメント結合転写因子1(srebf1)阻害剤による上昇した脂質レベルの治療
US20120183961A1 (en) Method for functional testing of site-specific dna methylation
MacLaren et al. Expression profiling identifies novel candidate genes for ethanol sensitivity QTLs
JP2024521754A5 (https=)
RU2021122161A (ru) Лечение респираторных нарушений с помощью ингибиторов арахидонат 15-липоксигеназы (alox15)
Hishinuma et al. TTF-2 stimulates expression of 17 genes, including one novel thyroid-specific gene which might be involved in thyroid development
JPWO2021262601A5 (https=)
RU2021121850A (ru) Лечение офтальмологических патологических состояний ингибиторами ангиопоэтин-подобного белка 7 (angptl7)
JPWO2020191141A5 (https=)
RU2023131494A (ru) Лечение цереброваскулярного заболевания с помощью агентов - белков-гомологов 3 нейрогенного локуса notch (notch3)